Clinical Trial: NCT04995523
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2026-07-14 |
Study Overview
Brief Summary
This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.
Official Title
Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
Conditions
Non-Small-Cell Lung Carcinoma
Intervention / Treatment
- Drug: AZD2936
Other Study ID Numbers
- D7020C00001
- 2023-508262-15-00
- 2021-000857-23
- 2023
Start Date (Actual)
2021-09-14
Primary Completion Date (Estimated)
2026-08-28
Study Completion Date (Estimated)
2028-06-01
Enrollment (Actual)
212
Study Type
Interventional
Phase
Phase 1, Phase 2
| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2026-07-14 |
Study Overview
Brief Summary
This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.
Official Title
Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
Conditions
Non-Small-Cell Lung Carcinoma
Intervention / Treatment
- Drug: AZD2936
Other Study ID Numbers
- D7020C00001
- 2023-508262-15-00
- 2021-000857-23
- 2023
Start Date (Actual)
2021-09-14
Primary Completion Date (Estimated)
2026-08-28
Study Completion Date (Estimated)
2028-06-01
Enrollment (Actual)
212
Study Type
Interventional
Phase
Phase 1, Phase 2